1 / 32

Molecular testing of thyroid nodules

Dr Sarah J Johnson Consultant Cyto/histopathologist Newcastle upon Tyne. Molecular testing of thyroid nodules. This talk. Overview of molecular abnormalities in thyroid lesions Potential value Our own work.

mariah
Download Presentation

Molecular testing of thyroid nodules

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr Sarah J Johnson Consultant Cyto/histopathologist Newcastle upon Tyne Molecular testing of thyroid nodules

  2. This talk • Overview of molecular abnormalities in thyroid lesions • Potential value • Our own work

  3. Overview of molecular abnormalities(Nikiforov YE, Modern Pathology 2011;24:S34-43;Bhaijee F & Nikiforov YE. EndocrPathol 2011;22:126-133.Nikiforova MN & Nikiforov YE. Thyroid 2009;9:1351­1361. • Recent dramatic increase in understanding of molecular biology of thyroid cancer • Main four • BRAF and RAS point mutations • RET/PTC and PAX8/PPARγgene rearrangements • Others • PI3K/AKT signalling pathway - PDC • TP53 and CTNNB1 mutations – PDC, ATC • TRK rearrangement – PTC but rare

  4. Nikiforov Arch Pathol Lab Med 2011;135:569-77 Bhaijee & Nikiforov Endocr Pathol 2011;22:126-33 Nikiforova & Nikiforov Thyroid 2009;19(12)1351-61 Prevalence of mutations

  5. BRAF point mutations • Intracellular effector of MAPK signalling cascade • Most V600E → activate BRAF kinase, stimulate MAPK pathway → tumourigenic for thyroid cells • 1-2% - other mutations egK601E • BRAF V600E mutation • quite specific for PTC and related tumour types • 60% classical PTC • 80% tall cell variant PTC • 10% FVPTC • 10-15% PDC • 20-30% ATC • NOT in FC, MTC or benign nodules • early in pathway

  6. BRAF - clinical and prognostic valueMelcket alThe Oncologist 2010;15:1285-93; Yip et al.Surgery2009;146:1215-23; Xing et al J ClinOncol2009;27:2977-2982. • Associated with aggressive tumour characteristics (V600E only) • ETE, multicentricity, advanced stage, LN+, distant metastases, recurrence, persistence, re-operations, tall cell morphology, lymphovascular invasion, suspicious USS features • especially >65 yrs • Independent predictor of treatment failure, tumour recurrence, tumour-related death • Even in microPTC – associated with poorer clinicopathological features (eg ETE, LN+) – exciting because management debated • May relate to • tendency to de-differentiate • reduced ability to trap radio-iodine • less responsive to TSH suppression

  7. BRAF – diagnostic value in cytologyAdeniran et al Thyroid 2011;21(7):717-23. Bentzet al Otolaryngol Head and Neck Surgery 2009;140:709-14 • BRAF mutation strongly correlates with PTC, independent of cytology • Improves accuracy, specificity and PPV for PTC • Specificity and PPV for PTC with BRAF-positivity = virtually 100% • Mixed results for sensitivity & NPV, can be low • Helpful in identifying PTC in “indeterminate” cytology samples • Could use to change management decision positive Total thyroidectomy +/ level VI LNs Indeterminate cytology BRAF test negative Diagnostic hemithyroidectomy

  8. BRAF –accuracy in cytology • 6 false positives for malignancy with BRAF analysis • 1 case in Korea – indeterminate cytology, BRAF-positive → histology of “atypical nodular hyperplasia” • 5 when ultrasensitive testing used, not positive on repeat testing • Recent meta-analysis – BRAF testing in 2766 samples • 581 BRAF-positive → 580 were PTC (some with benign cytology) • rate of malignancy for BRAF-positivity = 99.8% • frequency of indeterminate cytology in BRAF-positive samples = 15-39% • Various techniques possible but need to avoid ultrasensitive detection and methods that are not well validated → may risk false positives • BRAF detection in cytology also predicts aggressiveness • BRAF-negativity with indeterminate cytology does not eliminate need for diagnostic hemithyroidectomy

  9. BRAF –therapeutic value • Predicts aggressiveness →maybe consider more aggressive treatment, more frequent follow-up, but maybe not enough to act on yet • Therapeutic target - BRAF inhibitors eg sorafenib

  10. RAS - point mutations • Family includes HRAS, NRAS, KRAS • Propagate signals along MAPK and other signalling cascades • Most frequent mutations in thyroid • NRAS codon 61 • HRAS codon 61 • Found in • 10-20% PTC – mostly FVPTC • 40-50% FC • 20-40% FA – but ?precursors for FC • some hyperplastic nodules but clonal so ?neoplasm • less in oncocytic tumours

  11. RAS - point mutations • Prognosis • some association with dedifferentiation and worse outlook • but also associated with eFVPTC – indolent behaviour • Finding RAS mutation in thyroid nodule • strong evidence for neoplasia • but does not establish diagnosis of malignancy • RAS mutation in cytology • PPV for malignancy 74-88% • helpful when cytology difficult such as FVPTC

  12. RET/PTC gene rearrangements • RET highly expressed in C cells, not follicular cells • But activated by RET/PTC rearrangement • 11 types, RET fusion to different genes • Commonest in thyroid cancer - RET/PTC1 & RET/PTC3 • All fusions activate MAPK signalling pathway • Variation in expression – needs to be “clonal”, ie majority • ClonalRET/PTC - reasonably specific for PTC • 10-20% PTC in adults • 50-80% PTC after radiation exposure (RET/PTC1 – classical PTC, RET/PTC3 – solid type PTC) • 40-70% PTC in children and young adults • Non-clonalRET/PTC – no diagnostic implications

  13. RET/PTC- prognosis and diagnosis • PTC with RET/PTC - younger age, classical PTC histology, high rate LN metastases • But varied views on overall prognostic value • Detection of clonal RET/PTC = strong indication PTC • Histology – not useful because classical so diagnosis clear • In FNA – can improve pre-operative diagnosis PTC but can have false positives

  14. PAX8/PPARγgene rearrangement • Fusion between PAX8 gene and perioxisomeproliferator-activated receptor (PPARγ) gene • Causes over-expression of PPARγprotein • Found in • 30-40% conventional FC • less often in oncocytic carcinomas • 5-38% FVPTC • 2-13% FA – often thick capsule, ?pre-FC or misdiagnosed • Often - younger age, smaller tumour, more frequent vascular invasion • Detection in histology not diagnostic of malignancy but should prompt exhaustive search for capsular or vascular invasion • Detection in FNA – typically malignant but numbers low

  15. Gene expression profilesBorup et al Endocr-Related Cancer 2010;17:691-708. Maenhautet al ClinOncol2011;23:282-288. Ferrazet al ClinEndocrinolMetab 2011;96(7):2016-2026 • mRNA • no ideal marker of PTC • lack of markers to distinguish FC from FA • slight difference between radiation-induced PTC and not • ?can measure different background susceptibilities to radiation • microRNAs • easier to extract from FNA than mRNA • possible future diagnostic potential • PTC & FC have different profile to normal thyroid

  16. Review of 20 studies of genetic testing Ferrazet al ClinEndocrinolMetab 2011;96(7):2016-2026 • Highest sensitivity with panel of markers • BUT more FP with panel than with single marker • Best if done on same material as used for cytology, not extra • Suggest Indeterm-inate cytology Panel of markers Negative group Malignancy risk down from 20% to 8-10% miRNA Cohort with 3% malignancy risk ?follow up with USS + repeat FNA

  17. Sample in special preservative solution → panel of 7 molecular markers Commercially available kits – USA

  18. Sample → cytopathology → inadequate, benign or malignant report indeterminates → gene expression Commercially available kits – USA

  19. Our own work in Newcastle • Initial project • Current BRAF pilot

  20. Initial project – BSCC presentation 2011S. Hardy, U.K. Mallick, P. Perros, S.J. Johnson, A. Curtis and D Bourn Aim: to set up and validate assays for detection of molecular markers in thyroid samples Retrospective – archival histology then cytology Panel of markers: • BRAF codon 600 • HRAS codon 61 on extracted DNA • KRAS codons 12/13 (melt curve analysis) • NRAS codon 61 • RET/PTC rearrangements on extracted RNA • PAX8/PPARγrearrangements (RT-PCR-based assays)

  21. Example data – NRAS codon 61 WT CONTROL CODON 61 (Q61K) CONTROL WT WT Q61K WT Q61K

  22. Results – point mutations on thyroid histology cases • 32 cases (patients), 36 blocks • 6 non-neoplastic nodules 0/6 0% • 5 follicular thyroid adenoma (FA) 0/6 0% • 5 follicular thyroid carcinoma (FC) 1/5 20% (NRAS codon 61) • 7 papillary thyroid carcinoma (PTC) 1/6 17%(BRAF v600E) • 4 “aggressive” PTC (aPTC) 4/4 100% (BRAF v600E) • 3 poorly differentiated carcinoma (PDC) 1/3 33% (NRAS codon 61) • 1 SCC 1/1 100%(NRAScodon 61) • 1 metastatic strumaovarii 1/1 100%(NRAS codon 61) • ie. pattern as expected • Concordance between different blocks from same tumour

  23. Results – point mutations on cytology slides Cases with molecular result available on histology: NNN 2 cases, 4 slides 1/3 50% cases (NRAS codon 61) FA 1 case, 1 slide 0/1 0% FC 4 cases, 7 slides 2/6 50% cases (1 NRAS, 1 HRAS) PTC 2 cases, 6 slides 1/3 17% (NRAS codon 61) aPTC 3 cases, 9 slides 4 tumour 3/3 100% (2 BRAF V600E, 1 HRAS codon 61) 5 LN/bed 1/3 50% cases (HRAS but in neg LN) PDC 1 case, 2 slides 0/2 0% Cases with no molecular result available on histology: Thy4 (histol = FA) 0/1 0% Thy3 (histol = FC) 0/1 0% Thy3f (histol = FC), 4 slides 2/2 100% (NRAS,HRAS)

  24. Results as cancer patients 23 cancer cases • 21 molecular results on histology • 9/21 mutations • 5 of 9 had molecular tests on cytology: 2 fails, 3 positive matches • 2 no molecular result on histology • 1/2 mutation on cytology ie. cytology found mutations in 57% (4/7)

  25. Results as mutations 13 cases with mutations (on cytology and/or histology) • 12 malignant outcome • 1 benign outcome 9 histology cases with mutations – all malignant outcomes 11 cytology slides with 12 mutations - 7 patients - 6 malignant outcomes

  26. Results as cytology slides • 37 cytology slides • 29 thyroid, 4 LN, 4 recurrences • Most were DQ slides • Failure rate 9of 37 = 24% • 1 LBC slide (SurePath) - paired DQ worked • 2 cyst fluid only (LN met) – failed (same case histology worked) • 2 unsatisfactory slides (1 thyroid, 1 bed) – a paired US worked • 1 with lots blood & colloid – paired slide worked • 2 Thy3f • 1 Thy5

  27. Results as cytology slides • 37 cytology slides • 24 slides with histology mutation result available • 9 in agreement for no mutation • 4 in agreement for presence of mutation • 5 discordances – mutations in cytol not histol, 4 malignant outcomes • 11 cytology pairs (2 slides from same specimen) • 4 matches – 1 fail, 1 NRAS, 2 no mutation • 7 mismatches – 3 with one fail, 2 NRAS v fail, 1 NRAS v no mutation, 1 BRAF V600E v HRAS codon 61 • 1 of 4 slides from same specimen • 2 fail, 1 NRAS & HRAS, 1 HRAS only

  28. Conclusions from initial study • Molecular testing for DNA point mutations is feasible in stained thyroid cytology samples • PPV 92% for malignant outcome • BUT • not always successful result • not always match of cytology with cytology, or cytology with histology • can have multiple mutations in one sample and/or tumour • can have mutations in negative LN cytology sample from cancer case • can have mutations in non-neoplastic nodules • Next step – prospective BRAF testing for 12 months • Molecular testing also feasible in histology of thyroid cancers – possible future role for individualised treatment and prognostication • Mutation-specific targeted therapies?

  29. Current BRAF Pilot • Prospective • 12 months BRAF testing on cytology reported as Thy3a, Thy3f, Thy4 and Thy5 PTC • No result to clinician, no action on result • Will then • correlate with surgical and histological outcome • assess whether BRAF result would have influenced management decision

  30. BRAF Pilot – results so far • Tested 14 cytology slides from 13 patients • Slide types • 12 DQ – all worked, even with heavy bloodstaining • 1 ICC for Tg on destained DQ – worked • 1 SurePath LBC – failed • Outcomes • 2 BRAF V600E mutations • LN5 met PTC (histol = classical & follicular variant, pT3 pN1b) • Thyroid Thy5 PTC (histol = classical multifocal, pT1b pN1b) • 11 wild type • 7 Thy3a - 1 with histol = FA • 3 Thyf - 1 with histol = dominant nodule with contralat PTC • 1 Thy5 ATC vs MM – histol = ATC

  31. Summary points for whole talk • Molecular testing of thyroid cytology and histology specimens is feasible in routine labs • Diagnostic aims • single stage theraeutic surgery for cancers • avoiding diagnostic hemithyroidectomies for benigns • BRAF mutation shows most promise • diagnostically, prognostically & therapeutically • Other mutations and rearrangements • diagnostically & prognostically – less predictive • Also likely future role for microRNA studies

  32. Thankyou for listening

More Related